Salicylic Acid → (S)-5,11-Dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]thiazepine salicylate

HRID 1460474Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1460474
[C:1]([OH:10])(=[O:9])[C:2]1[C:3](=[CH:5][CH:6]=[CH:7][CH:8]=1)[OH:4].[CH3:11][O:12][C:13]1[CH:41]=[CH:40][C:16]([CH2:17][CH2:18][N:19]2[CH2:23][CH2:22][CH2:21][C@H:20]2[CH2:24][N:25]2[C:31]3[CH:32]=[CH:33][CH:34]=[CH:35][C:30]=3[CH2:29][S:28][C:27]3[CH:36]=[CH:37][CH:38]=[CH:39][C:26]2=3)=[CH:15][CH:14]=1>CCOCC>[C:1]([OH:10])(=[O:9])[C:2]1[C:3](=[CH:5][CH:6]=[CH:7][CH:8]=1)[OH:4].[CH3:11][O:12][C:13]1[CH:14]=[CH:15][C:16]([CH2:17][CH2:18][N:19]2[CH2:23][CH2:22][CH2:21][C@H:20]2[CH2:24][N:25]2[C:31]3[CH:32]=[CH:33][CH:34]=[CH:35][C:30]=3[CH2:29][S:28][C:27]3[CH:36]=[CH:37][CH:38]=[CH:39][C:26]2=3)=[CH:40][CH:41]=1

Komponenten

4

Edukt 2

HCID 338Salicylic AcidHCID 9824029(S)-5,11-Dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]thiazepine

Produkt 1

HCID 67836566(S)-5,11-Dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]thiazepine salicylateAusbeute 71,3 %

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 3283Diethyl EtherLösungsmittel2×

Versuchsvorschrift

A solution of salicylic acid (800 mg) in ether (5 ml) was added to a solution of (S)-5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]thiazepine (see Examples 1 and 6) (2.50 g) in ether (10 ml) and the mixture was stirred at room temperature for 16 hours. The resulting precipitate was collected, dried and recrystallised from isopropyl acetate to give the title compound as colourless crystals, (2.35 g, 71%), m.p. 150°-151° C., [α]589 -40.6° (c=0.695 in ethanol).

Aufarbeitung

  1. customThe resulting precipitate was collected
  2. customdried
  3. customrecrystallised from isopropyl acetate

Quellen und Nachweise

ORD-Eintrag
ord-24b2560581c74b028d7ea6d88a7e61f0
Quelldatensatz
uspto-grants-1991_12
Patentnummer
US05071844

Notizen zur Reaktion

Wird geladen…